BSX stock lost -1.33% in total of its share price. The quarter’s number remained at par with the Zacks Consensus Estimate and in line with the upper end of the company’s adjusted EPS guidance range of 25-27 cents.
Advertisement
Shares of Boston Scientific are up 2.4% in pre-market trading at $24.24 as of 9:09 a.m. EDT.
BSX is now showing 1.37 billion shares outstanding as compared with the 1.35 billion total shares float.
On Thursday Benchmark reiterated its target for shares of Boston Scientific Corporation as “Buy” recommending a target price of 31 for investors; potentially meaning there is an increase of 27.36% from Boston Scientific Corporation’s share price of 24.34. Now shares have been rated as “Buy” from 9 Analysts. Following the transaction, the executive vice president now directly owns 308,724 shares of the company’s stock, valued at $6,770,317.32. The business earned $2.13 billion during the quarter, compared to analyst estimates of $2.05 billion. The latest trading activity showed that the Boston Scientific Corp price went down -1.92% from its 52-week low and trades up 69.11% versus its 52-week high. Boston Scientific Corp. has an average rating of “Buy” and an average price target of $24.10. The earnings-per-share consensus range is $0.26-$0.28 on sales between $2.02B and $2.06B. The shares closed down -0.31 points or -0.25% at $124.46 with 4.32 million shares getting traded. In the past 52 weeks, the equity’s price traded between $85.63 and $ 120.43.
In Boston Scientific Corporation (NYSE:BSX)’s most recent quarter, EPS moved to $0.28 from $0.26 in prior quarter and revenues reached at $1,964.00M versus $1,978.00M.
Geographically, in the second quarter, the company achieved 154% growth in the US (8% organic), 16% growth in Europe (9%), 18% in the Asia, Middle East and Africa (AMEA) region (16%) and 8% in the emerging markets (20%), all at CER.
Boston Scientific Corp. (NYSE:BSX) last announced its earnings results on Thursday, July 28th.
For the second quarter the company said it lost $207 million, or 15 cents per share.
Advertisement
The 7 analysts offering 12-month price forecasts for Array Biopharma Inc have a median target of 7.00, with a high estimate of 13.00 and a low estimate of 7.00. Its revenue rose 15 percent from a year ago to $2.13 billion. “Underperform” verdict was shared by 1 analyst and “Overweight” recommendation was issued by 8 analyst. The stock attained the volume of 2.53M shares. The stock was sold at an average price of $24.03, for a total transaction of $841,050.00. Artemis Investment Management LLP now owns 1,119,418 shares of the company’s stock valued at $26,148,000 after buying an additional 224,100 shares during the last quarter. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
